Boryeong Hosts Ducab Plus Launch Symposium

[Asia Economy Reporter Chunhee Lee] Boryung (formerly Boryung Pharmaceutical) announced on the 27th that it held a launching symposium on the 25th under the themes of "The Blood Pressure-Lowering Effect of Dukab Plus" and "Recent Clinical Results on Pimasartan, the Main Ingredient of Dukab Plus" to commemorate the launch of the triple combination antihypertensive drug, Dukab Plus.

The symposium was held simultaneously in six regions including Seoul, Busan, Gwangju, Daejeon, Daegu, and Jeju. In particular, the symposium held at the Shilla Hotel in Seoul was attended by 360 medical professionals, and a total of about 1,000 medical professionals nationwide participated, concluding successfully.

Dukab Plus is the first triple combination antihypertensive drug based on Kanarb (active ingredient Pimasartan), an angiotensin II receptor blocker (ARB), combined with the calcium channel blocker (CCB) amlodipine and the diuretic hydrochlorothiazide. Notably, it comes in a small pill about 1 cm in size, improving patient medication adherence. Boryung received approval from the Ministry of Food and Drug Safety in March for three dosages of Dukab Plus tablets (30/5/12.5 mg, 60/5/12.5 mg, 60/10/12.5 mg) and plans to launch the product on the 1st of next month.

Dukab Plus has been confirmed to show a stronger blood pressure-lowering effect in patients with essential hypertension whose blood pressure was not controlled by Dukab, the existing dual combination drug containing pimasartan and amlodipine. According to phase 3 clinical trial results, in hypertensive patients uncontrolled by Dukab, administration of Dukab Plus resulted in a rapid decrease in systolic blood pressure (siSBP) by 9.84 mmHg within 2 weeks, and an additional maximum reduction of 19.05 mmHg by week 8. Furthermore, at week 8, 67.7% of patients achieved blood pressure normalization (systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg).

Through the launch of Dukab Plus, Boryung plans to further expand the Kanarb lineup and continue to increase its market share in the antihypertensive drug market. Since launching Kanarb, the first and only new antihypertensive drug in Korea in 2011, Boryung has released various combination drugs. Dukab Plus is the sixth product in the Kanarb family, following Kanarb, Dukab, Tubero, Dukaro, and Akab.

Boryung plans to hold an online symposium on its own medical information portal, Bridge, starting with this offline symposium. From the 30th of this month to the 3rd of next month, an online symposium week called "Webinar Week" will be held, featuring Dukab Plus and various other products.

Jang Doohyun, CEO of Boryung, stated, "With the launch of Dukab Plus, we can offer more diverse treatment options to hypertensive patients and medical professionals," adding, "Based on the diverse Kanarb lineup, we will lead the markets for hypertension and dyslipidemia treatments."